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Background: Modification of splicing by chemotherapeutic drugs has usually been evaluated on a limited number
of pre-mRNAs selected for their recognized or potential importance in cell proliferation or apoptosis. However, the
pathways linking splicing alterations to the efficiency of cancer therapy remain unclear.
Methods: Next-generation sequencing was used to analyse the transcriptome of breast carcinoma cells treated by
cisplatin. Pharmacological inhibitors, RNA interference, cells deficient in specific signalling pathways, RT-PCR and
FACS analysis were used to investigate how the anti-cancer drug cisplatin affected alternative splicing and the cell
death pathway.
Results: We identified 717 splicing events affected by cisplatin, including 245 events involving cassette exons.
Gene ontology analysis indicates that cell cycle, mRNA processing and pre-mRNA splicing were the main pathways
affected. Importantly, the cisplatin–induced splicing alterations required class I PI3Ks P110β but not components
such as ATM, ATR and p53 that are involved in the DNA damage response. The siRNA-mediated depletion of the
splicing regulator SRSF4, but not SRSF6, expression abrogated many of the splicing alterations as well as cell death
induced by cisplatin.
Conclusion: Many of the splicing alterations induced by cisplatin are caused by SRSF4 and they contribute to
apoptosis in a process requires class I PI3K.
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Chemotherapy with platinum-based compounds is used
extensively for the treatment of a wide range of solid
tumours, including breast cancers resistant to first line
therapy, ovarian, non-small cell lung, testis, endometrial,
head and neck and colorectal cancers. Cisplatin (cis-
diamine platinum (II) dichloride), the founding member
of this class of agents, covalently binds to DNA and
induces the formation of bulky DNA adducts consisting
of intra-strand cross-links preferentially formed between
adjacent guanine residues and, to a lower extent, inter-* Correspondence: maude.gabriel@ulg.ac.be
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unless otherwise stated.strand DNA lesions [1,2]. Cell toxicity is linked to these
adducts that interfere with DNA replication and tran-
scription. Intra-strand cross-links are mainly processed
by removal of platinum adducts via the nucleotide exci-
sion repair, and inter-strand cross-links are removed via
nucleotide excision repair, translesion polymerase and
homologous recombination. Cisplatin activates various
signalling pathways that include the DNA damage re-
sponse (DDR) and the PI3K-Akt pathways [1]. The DDR
pathway detects and corrects DNA defects. However,
when alterations are too numerous or too severe, cells
are committed to death and eliminated. The DDR ma-
chinery relies on the activity of three enzymes that belong
to the phosphatidyl inositol-3 kinases (PI3K) family:
DNA-protein kinase (DNA-PK), Ataxia and Telangectasia
Mutated (ATM) and Ataxia Telangiectasia and Rad. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and overlapping cascades of signalling events that re-
sult in cell cycle arrest, DNA repair or cell death [4].
Alternative splicing (AS) occurs in more than 90% of
multi-exons primary transcripts [4,5]. Proteins produced
through AS can have markedly different and sometimes
opposite functions, as exemplified by a number of fac-
tors involved in apoptosis or cell survival [6]. In other
instances, AS controls the level of proteins by producing
transcripts carrying premature termination codons that are
degraded by non-sense mediated RNA decay (NMD) [7].
Splicing decisions result from an interplay between highly
degenerated cis-acting sequences and a large number of
trans-acting factors that include the arginine- and serine-
rich proteins (SR-proteins) and the heterogenous nuclear
ribonucleoproteins (hnRNPs) families [8]. The participa-
tion of these factors in splicing control is often regulated
by post-translational modifications such as phosphory-
lation and acetylation which affect their localisation and
their interaction with other proteins [8].
Aberrant AS occurs in cancer and a growing number
of studies have reported a functional link between spli-
cing anomalies and the evolution of the disease [9-12].
Several groups, including ours, have shown that che-
motherapeutic drugs can affect the AS of a large number
of transcripts [13-16]. However, the impact of these
changes on the cancer cell is still poorly understood.
Here, we analyse the transcriptome of cisplatin-treated
cancer cells, and use AS changes to identify pathways
that link cisplatin with the cellular response.Methods
Cell culture, authentication, reagent and survival assay
MCF7, MDA-MB-231, HT1080, BT549, RD, HDF1
and HDF2, MG-63, MSU and AT5BIVA (deficient in
ATM, Coriell Cell Repository, Camden, NJ, USA) cells
were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM, Lonza, Verviers, Belgium) supplemented with
non-essential amino-acids (NEAA) (1%), penicillin and
streptomycine (1%), gentamycin (0.1%), fungizone (0.1%)
and 10% FCS (Lonza). Ishikawa cells (human endome-
trial adenocarcinoma cell line) were cultured in RPMI
1640-glutamax (Lonza) supplemented with NEAA (1%),
sodium pyruvate (1%), penicillin and streptomycine
(1%), fungizone (0.1%) and 10% FCS, GM09607 cells
(deficient in ATM, Coriell Cell Repository) in EMEM
(Lonza) supplemented with 10% FCS and 1% NEAA,
and MO59J cells (glioblastoma cell line, deficient in the
catalytic subunit of DNA-PK) in DMEM/F12 supple-
mented as DMEM.
The study conforms to the principles outlined in the
Declaration of Helsinki and was approved by the ethic
committee of Liège University Hospital (B707201110973).MCF7 and Ishikawa cells were authenticated by DSMZ
(Braunschweig, Germany). Although no authentication
of the other cell lines was made, the deficiency in ATM
of GM09607 and AT5BIVA was ascertained by western
blotting, and that of p53 in MG-63 was confirmed by
RT-PCR.
Cisplatin (cis-diamine platinum (II) dichloride), wort-
mannin, caffein, and triciribine were from Sigma-Aldrich
(St-Louis, MO, USA), oxaliplatin from Santa Cruz
Biotechnology (Santa Cruz, CA, USA), ATM kinase
inhibitor from Calbiochem EMD biosciences (La Jolla,
CA, USA), NU7026 from Merck Millipore (Darmstadt,
Germany), TGX221, IC87114 and MK2206 from Selleckchem
(Munich, Germany) and PX866 from LC Laboratories
(Woburn, MA, USA).
Cell survival and apoptosis/necrosis were measured,
respectively, by trypan blue exclusion in blind tests and
by FACS analysis as described in [17].
RNA isolation, RT-PCR and RT-qPCR
RNAs were purified from cultured cells using the High
Pure RNA isolation kit (Roche, Mannheim, Germany) and
quantified by spectrometry. Gene expression was mea-
sured by RT-qPCR. Details according to the Minimum
Information for Quantitative RT-PCR Experiment (MIQE)
guidelines [18], are given in Additional files 1 and 2. For
analysis of exon inclusion/exclusion, primers were chosen
on exons surrounding the sequences potentially alterna-
tively spliced. Primers, protocols and amplification pro-
ducts sizes are detailed in Additional file 2. Splice variants
were discriminated by electrophoresis as described [17].
RNA sequencing analysis
RNA libraries and sequencing were performed on total
RNA samples at the GIGA Genomics facility, University
of Liège, Belgium. The quality of RNA was checked with
BioAnalyser 2100 (Agilent technologies, CA, USA) that
indicated a RQI score >8. The libraries were prepared
with Truseq® mRNA Sample Prep kit (Illumina, CA,
USA) from 1 microgram of total RNA following manu-
facturer’s instructions. mRNAs were isolated by poly-A
selection and fragmented (8 minutes at 94°C). Fragmen-
ted mRNAs (around 170 nucleotide-long in average)
were used for reverse-transcription in the presence of
Superscript II (Invitrogen, Oregon, USA) and random
primers. After second strand synthesis, end-repair, A-
tailing and purification, the double strand cDNA frag-
ments were ligated to Truseq® adapters containing the
index sequences. Fifteen cycles of PCR in the presence
of dedicated PCR primers and PCR master mix were
applied to generate the final libraries. Libraries were
sequenced in pair-end sequencing runs on the Illumina
GAIIx in multiplexed 2 × 76 base protocols. The raw
data was generated through CASAVA 1.6 suite (Illumina,
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index.shtml) software was used to align RNA-Seq reads to
the reference genome (hg19, UCSA) and discover tran-
script splice sites. Cufflinks (http://cole-trapnelllab.github.
io/cufflinks/) used the resulting alignment files to quantify
the gene expression levels, identify up- and down-regulated
transcripts and find the alternative splice junctions.
SpliceSeq(1.2) (http://bioinformatics.mdanderson.org/main/
SpliceSeq:Overview) was used for a focused AS analysis.
Using alignment database and Bowtie, SpliceSeq aligns
reads from RNA-Seq data to a reference collection of
splice variants [19,20].
Gene prioritarization
Lists of genes modulated in term of expression and splicing
were imported in the ToppGene Suite for analysis [21].
Antibodies and Western blotting
Antibodies directed against Akt, phospho-Akt (ser473)
and β-actin were purchased from Cell Signalling (Beverly,
MA, USA). Cells were lysed in Laemmli buffer containing
50 mM DTT. Lysates were briefly sonicated, incubated at
65°C for 15 min and analyzed by SDS-PAGE. Proteins
were electroblotted and detected as described in [17].
Probing of β-actin was performed as a control of protein
loading.
siRNA transfection
SMARTpool siGENOME (Dharmacon by Thermo Fisher
Scientific, Lafayette, CO, USA), consisting of four siRNA
duplexes, were used to target SRSF4 and SRSF6 mRNA.
siRNA targeting ATR were from Ambion (Life tech-
nologies). The 5′-UUGCAUACAGGACUCGUUATT-3′
and 5′-UAACGAGUCCUGUAUGCAATT-3′ oligoribo-
nucleotides were used as control siRNA (siSCR) that
does not target any known human transcript [22]. Cells
were transfected by siRNAs as previously described [23].
Statistics
The means and standard deviation were calculated from
three or four independent experiments. The significance
of differences was determined using t-test or ratio paired
t-test of Student.
Results
Cisplatin alters alternative splicing
In vitro treatment of cells by cisplatin induces alterations
of splicing in various transcripts [15,24,25]. Following
treatment of MCF7 and Ishikawa cell lines with cisplatin
(Figure 1A-B), the RT-PCR analysis of MDM2, a negative
regulator of p53, showed a reduction in the full length
product and the appearance of smaller splicing variants.
The smallest variant had the expected size of MDM2-
ALT1 splice variant. This splicing shift was maximal at50 – 100 μM of cisplatin (Figure 1A-B) and after 24 –
48 hours (Figure 1E). A similar dose-dependent shift was
obtained with VEGF where cisplatin decreased the expres-
sion of VEGF-165 and concomitantly increased the pro-
duction of the VEGF-111 splice variant (Figure 1C-D).
Similar alterations of splicing of MDM2 were also ob-
served in MDA-MB-231 (breast adenosarcoma), BT549
(breast carcinoma), HT1080 (fibrosarcoma), RD (rhabdo-
myosarcoma), MG-63 (osteosarcoma), MSU (fibrobastic
cell line) and HDF1 and 2 (primary dermal fibroblasts)
cells treated with 50 μM cisplatin for 24 hours (Figure 1F).
The cisplatin analog oxaliplatin induced similar effects on
MDM2 splicing, suggesting that this splicing alteration is
generalized to platinum-based agents (Figure 1G).
Deep sequencing
Poly A+ RNA from MCF7 cells untreated or treated
with 50 μM cisplatin for 24 hours was isolated and pre-
pared for next-generation sequencing analysis. No sig-
nificant cell death over untreated samples was noted in
these conditions (as measured by trypan blue exclusion).
The average number of reads approached or exceeded
20 millions in both samples. Alignment of transcripts to
the genome indicated that 16733 and 16969 genes were
expressed in the control and cisplatin-treated samples,
respectively. Sequencing data are available in the ArrayEx-
press database (www.ebi.ac.uk/arrayexpress) under acces-
sion number E-MTAB-2663. The global gene expression in
the two conditions was highly correlated, with a Pearson
correlation coefficient = 0.835 (p = 0.000000).
Effect of cisplatin on gene expression
For differential gene expression, the following filters
were applied: absolute fold change >2 and q-value < 0.05.
Five hundred fifty-three genes were regulated (111 up
and 442 down, Additional file 3). The top 20 up-
regulated and down-regulated genes are listed in Table 1
with SERPINB5 (126×) and GPHN (159×) being first in
each category, respectively. The expression of a panel of
genes commonly used as calibrators was not significantly
affected (GAPDH: 1.20; ACTB: 0.79; ACTG: 0.93; PPIA
(cyclophylin A): 0.94; PPIB (cyclophylin B): 1.07). RT-
qPCR was performed to confirm the expression level of 9
up-, down- or non-regulated genes on the samples used
for RNA-Seq. Selected genes were either conventional
calibrators (GAPDH, ACTB, β2M) or encoded proto-
oncogenes (MYB, SERPINB5, JAK2), anti-oncogenes
(BRCA1, RB1) and a factor regulating apoptosis (FAS).
RT-qPCR analysis correlated with RNA-seq data with a
Pearson coefficient of 0.98 (p = 0.000004), validating the
RNA-seq data. Moreover, these changes in gene ex-
pression noted by RT-qPCR were confirmed in three
independent experiments using MCF7 cells, and in two
independent experiments in Ishikawa cells, indicating
Figure 1 Platinum-based chemotherapeutic agents affect MDM2 and VEGF pre-mRNA splicing. A-D: MCF7 and Ishikawa cells were treated
with the indicated concentrations of cisplatin and harvested after 24 hours. E: MCF7 cells treated with cisplatin (50 μM) were harvested at the
indicated times. F: The indicated cells were treated with cisplatin (50 μM) for 24 hours. G: MCF7 cells were treated with oxaliplatin at 50 μM and
harvested after 24 hours. Analysis of the splicing of MDM2 (A,B,E-G) or of VEGF-A (C,D) transcripts was performed by end-point RT-PCR and
acrylamide gel electrophoresis as detailed in Methods. Illustrated gels are representative of three independent experiments. FL: Full Length; ALT1:
Splice variant of MDM2.
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MCF7 cells.
Gene ontology analysis was performed using the
ToppFun Suite software. Significantly (p < 0.05) affected
biological processes were identified (Table 2). Many
genes regulated by cisplatin belong to two main groups:
cell cycle and proliferation. Surprisingly, neurogenesis
also appeared as a regulated category.
ToppFun identified genes matching annotations for tran-
scription factors PITX2 (38 genes), E2F (18 genes, Table 3)
and FOXF2 (19 genes). For genes matching with PITX2
and FOX2, no significant difference in the proportion of
up- and down-regulated genes (versus total numbers ofup- and down-regulated genes, respectively) was observed.
In contrast, the 18 genes matching with E2F were all
down-regulated. As the expression of E2F transcription
factors themselves was not significantly changed, this sug-
gests that cisplatin may affect their activity.
The list of genes regulated by cisplatin was compared to
lists of oncogenes (http://www.uniprot.org/uniprot/?query=
keyword:KW-0656) and tumor suppressors (http://www.
uniprot.org/uniprot/?query=keyword:KW-0043). Data
showed that cisplatin reduced the level of some tumor
suppressor genes and of oncogenes while inducing others
(Table 4). Strikingly, the expression of the two AP-1 mem-
bers FOS and JUN was found to be increased.
Table 1 Top twenty up- and down-regulated genes by cisplatin in MCF7 cells
Gene Name Fold_change q_value
SERPINB5 serpin peptidase inhibitor, Clade B (Ovalbumin), member 5 126 1.54E-08
POU3F1 POU class 3 homeobox 1 105 6.15E-03
NKX1-2 NK1 homeobox 2 75 3.63E-02
LAMP3 lysosomal-associated membrane protein 3 63 2.28E-02
ATF3 activating transcription factor 3 51 3.58E-07
GADD45A growth arrest and DNA-damage-inducible, alpha 51 1.51E-07
HBEGF heparin-binding EGF-like growth factor 44 8.31E-06
HES2 hairy and enhancer of split 2 (Drosophila) 41 3.59E-05
NGFR nerve growth factor receptor 41 4.80E-04
SNAI1 snail family zinc finger 1 32 1.82E-03
GPR3 G protein-coupled receptor 3 32 4.17E-03
GPR172B solute carrier family 52, riboflavin transporter, member 1 29 2.38E-03
PTAFR platelet-activating factor receptor 28 2.45E-04
PRODH proline dehydrogenase (oxidase) 1 27 2.92E-02
C5orf4 chromosome 13 open reading frame, human 27 2.07E-03
PMAIP1 phorbol-12-myristate-13-acetate-induced protein 1 22 1.26E-06
HAP1 huntingtin-associated protein 1 21 3.08E-02
FAS TNF receptor superfamily member 6 21 4.92E-05
GUCA1B guanylate cyclase activator 1B (retina) 20 4.71E-03
LIF leukemia inhibitory factor 19 5.31E-05
ROBO1 roundabout, axon guidance receptor, homolog 1 −46 2.45E-06
NEGR1 neuronal growth regulator 1 −48 7.78E-04
EYA4 eyes absent homolog 4 −49 3.90E-03
CADPS2 Ca++ − dependent secretion activator 2 −49 7.97E-03
SLCO3A1 solute carrier organic anion transporter family, member 3A1 −49 3.07E-02
SAMD12 sterile alpha motif domain containing 12 −50 4.74E-04
NFIA nuclear factor I/A −53 2.38E-04
SULF1 sulfatase 1 −55 6.43E-04
MAGI1 membrane associated guanylate kinase, WW and PDZ domain containing 1 −56 5.79E-05
HS6ST3 heparan sulfate 6-O-sulfotransferase 3 −62 1.80E-04
PLCH1 phospholipase C, eta 1 −62 2.47E-03
PPP1R9A protein phosphatase 1, regulatory subunit 9A −67 1.24E-03
KCNJ8 potassium inwardly-rectifying channel, subfamily J, member 8 −67 3.33E-04
MLLT3 myeloid/lymphoid or mixed-lineage leukemia translocated to, 3 −67 1.50E-02
PLXDC2 plexin domain containing 2 −70 2.52E-04
SEMA5A semaphorin 5A −75 1.50E-04
ERBB4 v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) −81 7.36E-04
LTBP1 latent transforming growth factor beta binding protein 1 −94 3.39E-05
TIAM1 T-cell lymphoma invasion and metastasis 1 −146 8.42E-03
GPHN Gephyrin −159 3.85E-05
Fold change expression in cisplatin-treated (50 μM, 24 hours) samples relative to control and q-values as measured by RNA-seq are indicated.
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Potential modifications of splicing by cisplatin were
investigated from the RNA-seq data. The SpliceSeqsoftware identified 717 AS events occurring in 619
primary transcripts (Additional file 4). Only 5 genes
(UGDH, SLC38A1, RETSAT, PDE8A, NASP) (0.44%)













Regulation of cell proliferation 0.002877 75 1189




Cell cycle process 0.03652 67 1070
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mRNA processing 5.512E-10 51 408
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Genes that were regulated by more than 2-fold (Expression) or transcripts
alternatively spliced (Splicing) by cisplatin were analysed by the ToppFun Suite
software. The identified biological processes are indicated.
Table 3 Genes regulated by cisplatin and matching
annotations for transcription factors E2F
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transcriptional levels. Changes in splicing were grouped
based on the type of events being affected: 79 changes
involved cassette exon inclusion events, 166 were cas-
sette exon exclusion events (of which 49% were not
annotated as alternative exons in NCBI), 243 changes
affected alternative 5′ or 3′ splice site selection events,
144 involved alternative promoters, 83 indicated alterna-
tive terminations and 2 were splicing changes attributed
to mutually exclusive exon. Significantly affected bio-
logical processes identified by ToppFun Suite software
on affected genes were “RNA splicing and processing”
and “cell cycle” (Table 2).
For validation purpose, 16 splicing events identified
by SpliceSeq as affected by cisplatin were evaluated by
RT-PCR. These events were chosen such as to cover the
range of AltSplice RPKM (reads per kilobase per million
reads) values from 0 to 40. RT-PCR confirmed the alter-
native splicing of the ten exon skipping events and four
of the six exon inclusion events in MCF7 and Ishikawa
cells, indicating a good concordance with RefSeq data(drawings of nine splicing events in MCF-7 cells are
shown in Figure 2).
PI3K pathway, but not DNA damage response and p53, is
involved in the alteration of splicing by cisplatin
As cisplatin induces DNA damage, the contribution of
three main actors of the DDR pathway (ATM, ATR and
DNA-PK) in cisplatin-induced exon inclusion/exclusion
was investigated. Cisplatin affected the splicing in ATM-
deficient AT5BIVA cells (illustrated for HNRNPDL exon
6 exclusion and exon 8 inclusion in Figure 3A) and
GM9607 cells (not illustrated). Similarly to its effect in
MCF7 cells (Figure 2), identical data were also found in
MO59J cells that lack the catalytic subunit of DNA-PK
(Figure 3B), and in MCF7 cells transfected with a siRNA
targeting ATR (not shown). Moreover, specific inhibition
of ATM (using ATM kinase inhibitor) or of DNA-PK
(using NU7026) did not reverse the splicing induced by
cisplatin in MCF7 cells (Figure 3C-D). Combined inhib-
ition experiments were performed to evaluate whether
the three DDR members might functionally compensate
each other. Inhibition of ATM and ATR (using caffeine)
and DNA-PK (using NU7026) failed to reverse the splicing
induced by cisplatin (Figure 3E-F). The same results were
obtained in MO59J cells (deficient in DNA-PK activity)
treated with caffeine (not shown). Together, these data
strongly suggest that the DDR does not participate in the
splicing change of HNRNPDLe6 and AMZ2 induced by
Table 4 Cisplatin regulates the expression of tumor
suppressors and oncogenes






























The fold change and p-value are indicated. The list of the genes regulated by
cisplatin was compared to lists of oncogenes (http://www.uniprot.org/uniprot/
?query=keyword:KW-0656) and tumours suppressors (http://www.uniprot.
org/uniprot/?query=keyword:KW-0043).
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larly not involved since cisplatin induces an alteration of
MDM2 splicing in the p53-deficient cell line MG-63
(Figure 1F).
As cisplatin is also known to activate PI3K in several
cell types [26], the implication of the PI3Ks in the AS
changes induced by cisplatin was evaluated. MCF7 cells
were pre-treated with wortmannin three hours prior to
adding cisplatin. At the concentrations used, wortman-
nin inhibits class I and III PI3Ks as well as PI3KC2b, but
not ATM, ATR, DNA-PK. Dose-dependent inhibition
of the effect of cisplatin on the splicing events was
observed (Figure 3G-J). A similar impact was observedwith the wortmannin derivative PX866 (Figure 3K-L).
To gain further insights into the identity of PI3Ks in-
volved, inhibitors specifically targeting the class I PI3Ks
(TGX211, IC87114) were used (Figure 4A-D). As ob-
served with wortmannin, these inhibitors significantly
reversed the cisplatin-induced splicing changes, while no
effect was observed in the absence of cisplatin. These
results suggest that the class I PI3Ks are involved in the
cisplatin-mediated response. RNA-Seq data indicate that
p110α and p110β, but not p110γ and p110δ, are ex-
pressed in MCF7 cells. P110α, but not p110β, is acti-
vated by insulin. At the concentration used, TGX221
and IC87114 did not reduce the phosphorylation of Akt
induced by insulin (not shown). Cisplatin treatment did
not induce Akt phosphorylation on Ser473 under our
experimental conditions (not shown). Moreover, the Akt
inhibitors triciribine and MK2206, while efficiently redu-
cing the insulin-induced phosphorylation of Akt, did not
affect the cisplatin-induced changes in splicing in AMZ2
and HNRNPDL-E6 (Figure 4E-H). Finally, insulin did
not induce a change in AS that was similar to cisplatin
in conditions that increase Akt phosphorylation (not
shown). Together, these observations strongly suggest
that the splicing alterations elicited by cisplatin require
p110β, but are independent of Akt.
Cisplatin-induced alteration of splicing involves SRSF4
Using a siRNA screen targeting 57 splicing factors, we
identified SRSF4 as a regulator of hnRNPDL exon 6
splicing in MCF7 cells in basal growth conditions. We
evaluated the role of SRSF4 in mediating the effect of
cisplatin on AS by using a siRNA targeting SRSF4 and a
control siRNA targeting the splicing factor SRSF6. Re-
duced levels of SRSF4 mRNA (81 ± 7% reduction, n = 3)
and SRSF6 mRNA (80 ± 10%, n = 3) were confirmed by
end-point RT-PCR (Figure 5A-B). siSRSF4 alone or
when combined to siSRSF6 (siSRSF4/6) partly abrogated
the splicing changes induced by cisplatin in the events
tested (Figure 5C-F). The control siSCR and siSRSF6
alone had no effect. A similar reduction of the cisplatin-
induced HNRNPDL exon 6 exclusion and exon 8 in-
clusion after knock-down of SRSF4 was observed in the
breast cancer cell line BT549 (not illustrated).
Cisplatin-induced cell death involves SRSF4
To address the potential involvement of SRSF4-dependent
splicing events induced by cisplatin in cell death or cell
survival, MCF7 cells transfected with the control siRNA
siSCR or with siSRSF4 were treated or not with cisplatin
for 48 hours. Apoptosis and necrosis were measured by
FACS (Figure 6A-D). Although the downregulation of
SRSF4 had no effect on growth when cisplatin was absent,
it strongly reduced cell death observed in the presence of
cisplatin (15 ± 4% for siSRSF4 versus 6 ± 2% for siSCR;
Figure 2 Analysis of selected splicing events modified by cisplatin in MCF7 cells. End-point RT-PCR and analysis of amplification products
by acrylamide gel electrophoresis were performed on control and cisplatin (50 μM, 24 hours)-treated MCF7 cells to validate inclusion/exclusion
events detected by RNA-Seq and SpliceSeq analysis. Cisplatin-treatment induced the inclusion of HNRNPDL exon 8 (E8; ***p = 0.0008), MTA1
exons 3–4 (E3-4; *p = 0.047) and NFE2L1 exon 5 (E5; **p = 0.008), and the exclusions of CSDE1 exons 2–4 (delta E2-4; ***p = 0.00003), HNRNPDL
exon 6 (delta E6; **p = 0.0045), EIF4A2 exon 4 (delta E4; * = 0.02), TMPO exons 6–8 (delta E6-8; **p = 0.009), AMZ2 exon 3 (delta E3; ***p = 0.001),
STRAP exon 2 (delta E2; p = 0.059) and MAGOH exon 3 (delta E3; * = 0.04). Graphs show the mean and SD and are representative of at least 3
independent experiments.
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induced cell death by SRSF4 repression (Figure 6E). These
data were further confirmed by using the trypan blue exclu-
sion assay (53 ± 3% reduction, p ≤ 0.01, n = 3, Figure 6E).
Discussion
The development of chemotherapeutic agents has enabled
tremendous progress in cancer therapy. However, the suc-
cess of these treatments is offset by the development of
drug resistance and by toxic side-effects on healthy cells
and tissues. The development of this resistance is encour-
aged by several processes, including decreased access and
increased efflux of the drug from the tumor, altered ex-
pression of oncogenes, reduced apoptosis and increased
DNA repair [27]. In order to evaluate the role of AS in the
efficiency of cisplatin, we performed a transcriptomeanalysis of breast cancer cell line because platinum-based
chemotherapy is used as second and third-line of treat-
ment against resistant metastatic breast cancer [28,29].
Moreover, MCF7 cells are well-characterized notably in
terms of their response to chemotherapeutic drugs. Our
results indicate that cisplatin affects the expression level
(absolute fold change >2) of more than 500 genes and
provokes changes in at least 700 splicing events, thereby
extending previous observations that chemotherapeutic
agents affect AS [6,13,16]. This splicing reprogramming
also occurs in other transformed cell lines including the
breast cancer cell lines MDA-MB-231 and BT549, the
endometrial adenocarcinoma cell line Ishikawa and in
primary fibroblasts.
Many of the genes whose expression is altered by cis-
platin have functions in cell cycle. Cisplatin-induced
Figure 3 Lack of contribution of ATM, ATR and DNA-PK pathways in cisplatin-induced splicing. AT5BIVA (ATM deficient, A) and MO59J
(DNA-PK deficient, B) cells were treated with cisplatin (50 μM, 24 hours) and analysed for alternative splicing events in HRNPDL pre-mRNA.
(*p ≤ 0.05; **p≤ 0.01); C-D: MCF7 cells were treated with ATM inhibitor (50 μM) or DNA-PK inhibitor (NU7026; 25 μM) three hours prior to
treatment with cisplatin (50 μM for 24 hours); E-F: MCF7 cells were pre-treated with caffeine (5 mM) and with DNA-PK inhibitor (NU7026; 25 μM) for
three hours prior to treatment with cisplatin (50 μM) (E: HNRNPDL-E6 p = 0.13; F: AMZ2: p = 0.49). G-L: MCF7 cells were treated with wortmannin
(100 nM and 500 nM) or PX866 (500 nM), three hours prior to treatment with cisplatin (50 μM, 24 hours). Modifications of alternative splicing were
evaluated for G: HNRNPDL-E6 *p = 0.02; H: HNRNPDL-E8 *p = 0.02; I: AMZ2 **p = 0.004, ***p = 0.0005; J: MDM2. Similar modification was observed with
PX866 and illustrated for K: HNRNPDL-E6 *p = 0.05; L: AMZ2 *p = 0.02. Alternative splicing was evaluated by end-point RT-PCR and acrylamide gel
electrophoresis. Each bar shows the mean with SD of at least three independent experiments.
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genes, oncogenes and genes involved in determining cell
fate (Table 4). Strikingly, the list lacks genes encoding
splicing factors, suggesting that the impact on splicing
control principally stems from post-transcriptional and/
or post-translational events affecting their expression,
localization and activity. In contrast, cisplatin affected
the AS of many splicing factors. Accordingly, our gene
ontology analysis suggests that splicing function may be
one of the pathways most affected by cisplatin.
We observed that other chemotherapeutic drugs,
namely camptothecin and doxorubicin, induce the samechanges in AS as those elicited by cisplatin (unpublished
work). As these drugs all induce DNA damage, it is tempt-
ing to speculate that activation of the DDR pathway may
be involved in promoting these splicing alterations. In
contrast to this prediction, the genetic depletion and/or
the specific inhibition of p53, ATM, ATR and DNA-PK
failed to suppress AS re-programming upon cisplatin
treatment. These data contrast with those of Shkreta et al.
[30] who observed that the shift in Bcl-x splicing induced
by oxaliplatin or cisplatin in HEK-293 cells was abrogated
by inhibiting ATM, ATR or p53. However, no significant
change in Bcl-x splicing by cisplatin was recorded here by
Figure 4 Involvement of PI3K pathway, but not Akt, in cisplatin-induced splicing. A-F: MCF7 cells were treated with TGX221 (5 μM; A-B) or
IC87114 (10 μM; C-D) three hours prior to treatment with cisplatin (50 μM, 24 hours). E-H: MCF7 cells were treated with triciribine (20 μM) or
MK2206 (2 μM) three hours before cisplatin treatment (50 μM; 24 hours). Alternative splicing of exon 6 of HNRNPDL (B,D,F,H) and exon 3 of
AMZ2 (A,C,E,G) was evaluated by RT-PCR. RT-PCR products were fractionated by gel electrophoresis.
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trated), consistent with the very small shift previously
observed in MCF7 cells [30]. These discrepancies may be
related to the different cell lines used, which may display
different thresholds to elicit the DNA damage response.
Previous reports indicate that the PI3K/Akt axis can
affect the AS of many primary transcripts at least in part
by activation of SRPK and the phosphorylation of SR
proteins [31-33]. We investigated the role of this path-
way in the AS changes induced by cisplatin by using a
panel of inhibitors. Our results indicate that cisplatin
alters AS in a process that requires the PI3K subunit
p110β. The link between p110β and the splicing events
altered by cisplatin remains unclear but is independentof Akt. An intriguing possibility is that cisplatin affects
the nuclear activity of p110β, which in turn may directly
affect the activity of splicing factors. A role for p110β is
not totally unexpected since there is mounting evidence
indicating that nuclear lipids can regulate nuclear func-
tions including splicing [34,35]. While phosphoinositides
associate with nuclear membranes, they also co-localize
in nuclear speckles [36] and interact with various
proteins or ribonucleoprotein complexes including the
spliceosome components U2 snRNP, U4/U6 snRNP and
SF3A1.
We observed that knocking down SRSF4, but not SRSF6,
abrogated the cisplatin-induced changes in splicing. CLIP
analysis followed by high-throughput sequencing identified
Figure 5 SRSF4 is involved in cisplatin-induced splicing. A-B: MCF7 cells were transfected with siRNA targeting SRSF4 or/and SRSF6. Cells
were harvested three days post-transfection and SRSF4 and SRSF6 mRNA levels were measured by end-point RT-PCR to control the efficiency of
the siRNA. C-F: the histograms and errors bars represent mean and SD, respectively, illustrating the inter-experiment differences in the percentage
of exon inclusion (n = 5 to 7). However, the statistics were made on the fold change measured in each independent experiment. MCF7 cells
transfected with control siRNA (siSCR) or siRNA targeting SRSF4, SRSF6 or both were treated with cisplatin. The splicing of MDM2 (C), HNRNPDL-E6
(**p = 0.012; ***p = 0.0013) (D), HNRPDL-E8 (**p = 0.0163) (E) and AMZ2 (***p = 0.0002, **p = 0.001) (F) was evaluated by end-point RT-PCR.
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A/GA sequence as a con-
sensus motif for the binding of SRSF4 to RNA [37]. More-
over, SRSF4 preferentially binds to exons, with a peak of
binding ~50 nucleotides upstream of the 5′ splice site.
Sequences matching with these sequences are observed in
the exons that were skipped in response to cisplatin. How-
ever, that they represent binding sites for SRSF4 remains to
be tested.
Although SRSF4 may also have an indirect function,
for example by regulating the splicing of other splicing
factors, we believe that this scenario is unlikely to ex-
plain the rapid changes in the steady state levels of splice
variants imposed by cisplatin. Nevertheless, portions ofthe RS-rich regions of SRSF3 and SRSF7 are truncated
due to exon skipping (SRSF7) or alternative termination
(SRSF3) in response to cisplatin treatment, thereby pos-
sibly affecting the phosphorylation of these proteins and
their association with other splicing partners.
A link between altered splicing and the efficacy of can-
cer treatment is suggested by several findings. In lym-
phocytes of patients with chronic lymphocytic leukemia,
mutations in the gene encoding the splicing factor
SF3B1 are more frequent after treatment, suggesting a
chemotherapy-driven clonal selection for cells being af-
fected in splicing [38,39]. The efficacy of chemotherapetic
agents may act at least in part through reprogrammation
Figure 6 SRSF4 contributes to cisplatin-induced cell death. A-D: Apoptosis was measured by FACS after annexin V/propidium iodide staining
of siSCR (A,B) or siSRSF4 (C,D) transfected MCF-7 cells untreated (A,C) or treated with cisplatin (B,D; 50 μM, 24 hours). The percentages in each
quartile are mean values calculated from three independent experiments. E. Quantification of data from trypan blue exclusion and FACS analysis.
Histograms indicate cell death in siSRSF4 transfected MCF7 cells treated with cisplatin as compared to death in cells transfected with control
siRNA (siSCR) taken as 100%. Data were corrected for cell death measured in untreated cells. Each bar shows the mean with SD of three
independent experiments.
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cell line with a panel of chemotherapeutic agents induced
splicing shifts that encouraged the production of pro-
apoptotic variants of Bcl-x, caspase-9 and survivin [6].
Moreover, altering the ratio of splice variants of caspase-9
reduced the resistance of non-small lung cancer cells to
various chemotherapeutical agents [40]. On the contrary,
splicing switches toward anti-apoptotic versions, as in the
conversion from FAS to sFAS, have also been observed
([6] and personal observation). As high sFAS levels correl-
ate with poor survival in patients with T-cell leukemia and
gynecological malignancies [41,42], sFAS may contribute
to the acquisition of drug resistance and a chemotherapy
designed to revert splicing to FAS may increase treatment
efficiency [43].
GO terms related to apoptosis were not highlighted by
hierarchization analysis of the transcripts alternatively
spliced upon cisplatin. We compared a list of transcripts
related to apoptosis (GSEA [44,45]) with the list of
transcripts with splicing affected by cisplatin treatment.
Twenty-six actors involved in the regulation of apoptosis
were common to both lists, as for example BAX,
caspase-6, caspase-8 (pro-apoptotic) and MADD, API5
(anti-apoptotic). These examples illustrate that cisplatin-
induced alterations of splicing may have both anti- and
pro-apoptotic effects, and the net effect cannot be
estimated on a theoretical basis.
Here, we observed that knocking down SRSF4 reduced
the impact of cisplatin on cell death, suggesting an
overall therapeutic benefit associated with the expressionof SRSF4. Thus, while the pharmacological alterations
of splicing induced by chemotherapic agents may fuel
therapeutic efficiency, preventing these alterations by
inhibiting SRSF4-regulated splicing may help cells to resist
the cisplatin treatment. This situation is likely to be more
complex given the large number of splicing regulators,
their combinatorial mode of regulation and the diversity
of their targets. A growing list of pharmacological agents
that can modulate splicing is now emerging, with some
demonstrating anti-tumor activity [46-48]. Pladienolide,
spliceostatin and herboxidiene modulate the function of
the spliceosome by binding to the SF3B core component
protein [49,50]. A link between splicing alterations and
inhibition of cancer cell proliferation was established [50],
supporting the concept of using splicing to improve anti-
cancer therapy. Another example is provided by the anti-
hypertensive agent amiloride that also affects the level
and/or the phosphorylation of splicing factors, alters the
splicing of cancer genes in various tumor cell lines and
sensitizes chronic myelogenous leukemia cells to imatinib
[51]. Similarly, dietary agents possessing anticancer
activities as curcumin, resveratrol and epigallocatechin-
gallate, have been shown to affect splicing, at least in part
through modulation of splicing factors levels [52-55].
Conclusions
We showed that the reprogramming of splicing induced
by cisplatin makes a large contribution to its anti-cancer
property, and that its action requires class I PI3K p110β
and the splicing factor SRSF4. In this context, our data
Gabriel et al. BMC Cancer  (2015) 15:227 Page 13 of 14have two major implications. They suggest that phar-
macologically modulating AS can potentially affect the
success of chemotherapy. Moreover, they raise the inter-
esting possibility that molecules or conditions (as drugs
used for non-tumoral diseases, food components and
redox status) that modify AS may influence the response
to anti-cancer treatments.
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